Follow
Bennouna
Bennouna
Professeur d'oncologie médicale
Verified email at hopital-foch.com
Title
Cited by
Cited by
Year
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ...
New England journal of medicine 364 (19), 1817-1825, 2011
78192011
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ...
Journal of clinical oncology 31 (27), 3327-3334, 2013
36842013
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised …
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
17222015
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ...
The lancet oncology 14 (1), 29-37, 2013
13122013
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open …
L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ...
The Lancet Oncology 22 (2), 198-211, 2021
9242021
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
E Van Cutsem, WL Vervenne, J Bennouna, Y Humblet, S Gill, ...
Journal of clinical oncology 27 (13), 2231-2237, 2009
7832009
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 …
PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ...
Journal of Clinical Oncology 37 (4), 318-327, 2019
7192019
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ...
Journal of Clinical Oncology 38 (35), 4138-4148, 2020
6852020
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
E Quoix, G Zalcman, JP Oster, V Westeel, E Pichon, A Lavolé, J Dauba, ...
The Lancet 378 (9796), 1079-1088, 2011
6712011
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ...
Annals of Oncology 29 (8), 1807-1813, 2018
573*2018
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
HL Kindler, T Ioka, DJ Richel, J Bennouna, R Létourneau, T Okusaka, ...
The lancet oncology 12 (3), 256-262, 2011
4482011
Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients
F Denis, C Lethrosne, N Pourel, O Molinier, Y Pointreau, J Domont, ...
JNCI: Journal of the National Cancer Institute 109 (9), djx029, 2017
4412017
Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer
F Denis, E Basch, AL Septans, J Bennouna, T Urban, AC Dueck, ...
Jama 321 (3), 306-307, 2019
4232019
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small …
G Robinet, P Thomas, JL Breton, H Lena, S Gouva, G Dabouis, ...
Annals of oncology 12 (1), 59-67, 2001
3362001
Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma
SA Piha-Paul, SI Jalal, S Saraf, J Lunceford, M Lunceford, J Bennouna
ASCO, 2018
2912018
Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies
HC Chung, SA Piha-Paul, J Lopez-Martin, JHM Schellens, S Kao, ...
Journal of Thoracic Oncology 15 (4), 618-627, 2020
2882020
Vγ9Vδ2 T cell response to colon carcinoma cells
M Corvaisier, A Moreau-Aubry, E Diez, J Bennouna, JF Mosnier, E Scotet, ...
The Journal of Immunology 175 (8), 5481-5488, 2005
2872005
Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
J Bennouna, E Bompas, EM Neidhardt, F Rolland, I Philip, C Galéa, ...
Cancer immunology, immunotherapy 57, 1599-1609, 2008
2862008
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and …
B Melichar, A Adenis, AC Lockhart, J Bennouna, EC Dees, O Kayaleh, ...
The Lancet Oncology 16 (4), 395-405, 2015
2732015
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung …
JCH Yang, MH Schuler, N Yamamoto, KJ O'Byrne, V Hirsh, T Mok, ...
Journal of Clinical Oncology 30 (18_suppl), LBA7500-LBA7500, 2012
2582012
The system can't perform the operation now. Try again later.
Articles 1–20